Sonya Das1, Andrew W Lo2. 1. MIT Laboratory for Financial Engineering, Sloan School of Management, Cambridge, MA, United States; MIT Department of Mathematics, Cambridge, MA, United States. 2. MIT Laboratory for Financial Engineering, Sloan School of Management, Cambridge, MA, United States; MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, United States; MIT Department of Electrical Engineering and Computer Science, Cambridge, MA, United States; AlphaSimplex Group LLC, Cambridge, MA, United States. Electronic address: alo-admin@mit.edu.
Abstract
BACKGROUND: In this case study, we profile the I-SPY 2 TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And molecular anaLysis 2), a unique breast cancer clinical trial led by researchers at 20 leading cancer centers across the US, and examine its potential to serve as a model of drug development for other disease areas. This multicenter collaboration launched in 2010 to reengineer the drug development process to be more efficient and patient-centered. METHODS: We conduct several interviews with the I-SPY leadership as well as a literature review of relevant publications to assess the I-SPY 2 initiative. RESULTS: To date, six drugs have graduated from I-SPY 2, identified as excellent candidates for phase 3 trials in their corresponding tumor subtype, and several others have been or are still being evaluated. These trials are also more efficient, typically involving fewer subjects and reaching conclusions more quickly, and candidates have more than twice the predicted likelihood of success in a smaller phase 3 setting compared to traditional trials. CONCLUSIONS: We observe that I-SPY 2 possesses several novel features that could be used as a template for more efficient and cost effective drug development, namely its adaptive trial design; precompetitive network of stakeholders; and flexible infrastructure to accommodate innovation.
BACKGROUND: In this case study, we profile the I-SPY 2 TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And molecular anaLysis 2), a unique breast cancer clinical trial led by researchers at 20 leading cancer centers across the US, and examine its potential to serve as a model of drug development for other disease areas. This multicenter collaboration launched in 2010 to reengineer the drug development process to be more efficient and patient-centered. METHODS: We conduct several interviews with the I-SPY leadership as well as a literature review of relevant publications to assess the I-SPY 2 initiative. RESULTS: To date, six drugs have graduated from I-SPY 2, identified as excellent candidates for phase 3 trials in their corresponding tumor subtype, and several others have been or are still being evaluated. These trials are also more efficient, typically involving fewer subjects and reaching conclusions more quickly, and candidates have more than twice the predicted likelihood of success in a smaller phase 3 setting compared to traditional trials. CONCLUSIONS: We observe that I-SPY 2 possesses several novel features that could be used as a template for more efficient and cost effective drug development, namely its adaptive trial design; precompetitive network of stakeholders; and flexible infrastructure to accommodate innovation.
Authors: Dean Ho; Stephen R Quake; Edward R B McCabe; Wee Joo Chng; Edward K Chow; Xianting Ding; Bruce D Gelb; Geoffrey S Ginsburg; Jason Hassenstab; Chih-Ming Ho; William C Mobley; Garry P Nolan; Steven T Rosen; Patrick Tan; Yun Yen; Ali Zarrinpar Journal: Trends Biotechnol Date: 2020-01-21 Impact factor: 19.536
Authors: Theodore S Hong; Eliezer M Van Allen; Sophia C Kamran; Jochen K Lennerz; Claire A Margolis; David Liu; Brendan Reardon; Stephanie A Wankowicz; Emily E Van Seventer; Adam Tracy; Jennifer Y Wo; Scott L Carter; Henning Willers; Ryan B Corcoran Journal: Clin Cancer Res Date: 2019-06-28 Impact factor: 12.531
Authors: Joseph P Menetski; Steven C Hoffmann; Stephanie S Cush; Tania Nayak Kamphaus; Christopher P Austin; Paul L Herrling; John A Wagner Journal: Clin Pharmacol Ther Date: 2019-04 Impact factor: 6.875
Authors: Eric D Slosberg; Barinder P Kang; Julio Peguero; Matthew Taylor; Todd M Bauer; Donald A Berry; Fadi Braiteh; Alexander Spira; Funda Meric-Bernstam; Steven Stein; Sarina A Piha-Paul; August Salvado Journal: Oncotarget Date: 2018-04-20